S. 1407 · Where this bill is now
In committee
Introduced in the Senate, Apr 10, 2025
What this bill does
In plain words · AI-written from the official summaryShifts drug ingredients away from China
This bill phases in restrictions on federal health care programs, preventing them from purchasing drugs with active ingredients made in China or countries that don't meet FDA safety standards. By 2030, federal programs won't be able to buy these drugs unless the Department of Health and Human Services grants a waiver. The bill also requires all drugs to be labeled with the country where each active ingredient comes from, and offers tax breaks to companies that build or expand drug and medical device manufacturing facilities in the United States between 2025 and 2030.
How it affects you
If you get health care through a federal program like Medicare, Medicaid, or the Veterans Health Administration, your available medications could change as the rules phase in over the next several years. Pharmaceutical and medical device manufacturers may see new incentives to build factories in the U.S., which could affect where drugs are made, though the practical impact on drug prices and availability depends on how the transition unfolds.
Read the official summary (Introduced in Senate, Apr 10, 2025)
Anyone But China Safe Drug Act or the ABC Safe Drug Act
This bill restricts federal health care programs from purchasing drugs with active ingredients manufactured in China and provides tax incentives for the purchase of certain pharmaceutical and device manufacturing property for use in the United States.
The bill phases in restrictions on federal health care programs’ purchase of drugs. By January 1, 2030, federal health care programs may not purchase any drug that contains active ingredients from China or countries that do not meet the health and safety standards of the Food and Drug Administration. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement; this waiver authority expires in 2031.
The bill also requires all drugs to be labeled with the country of origin of each active ingredient in the drug. Drugs that are not labeled with this information are deemed misbranded.
Finally, the bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2025 and 2030. Qualified pharmaceutical and medical device manufacturing property is any tangible property placed in service in the United States as part of the construction or expansion of property for the manufacture of drugs or devices.
Written by AI (Claude) using only the official summary by the Congressional Research Service, the Library of Congress’s nonpartisan research staff. It can miss nuance, so check the official summary and the bill text for details.
1st SessionS. 1407
A BILL
ABC Safe Drug Act
Sponsor: Sen. Tom Cotton (R-AR) · Introduced Apr 10, 2025 · Health · 1 version of the text
Sources: Congress.gov actions and votes · bill text from GovInfo · latest official action Apr 10, 2025: “Read twice and referred to the Committee on Finance.”